Aim of this study is comparison effect of propofol and Dexmedetomidine in hemodynamic response in intubation. This study is clinical trial and double blind in emergency intubation in Valiasr hospital.114 patient divided randomly two groups(Propofol and Dexmedetomidin).At first we inject 2-3 micro gram per kilogram Fentanyl plus 2-3 Lidocaine 2% and 1-3 milligram Midazolam. So after Succinylcholine 1 milligram per kilogram. We inject 0/4 microgram per kilogram Dexmedetomidin in first group and 50-70 milligram per kilogram propofol in second group for hemodynamic response control in patient and intubation. We record hemodynamic sign include systolic blood pressure, diastolic blood pressure, mean arterial pressure, blood heart rate before and after intubation number of cough after intubation.
Inclusion criteria: ASA I and II; without chronic disease; lack of drug abuse; age 18-75; both of gender
Exclusion criteria: unwillingness to participate in the study.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT2016102520258N14
Registration date:2016-10-31, 1395/08/10
Registration timing:registered_while_recruiting
Last update:
Update count:0
Registration date
2016-10-31, 1395/08/10
Registrant information
Name
Fariba Farokhi
Name of organization / entity
Arak University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 86 3222 2003
Email address
f.farokhi@arakmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Vice President of Research Arak University of Medical Sciences
Expected recruitment start date
2016-10-09, 1395/07/18
Expected recruitment end date
2018-10-10, 1397/07/18
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison effect of propofol and Dexmedetomidine in hemodynamic response in emergency intubation
Public title
Comparison effect of propofol and Dexmedetomidine in hemodynamic response in emergency intubation
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: ASA I and II; without chronic disease; lack of drug abuse; age 18-75; both of gender
Exclusion criteria: Unwillingness to participate in the study
Age
From 18 years old to 75 years old
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size:
114
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee Arak University Of Medical Sciences